Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | PIK3CA |
| Variant | H1047L |
| Impact List | missense |
| Protein Effect | gain of function |
| Gene Variant Descriptions | PIK3CA H1047L is a hotspot mutation that lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). H1047L results in increased phosphorylation of Akt and Mek1/2, growth factor-independent cell survival, and transformation in cell culture (PMID: 26627007, PMID: 29533785). |
| Associated Drug Resistance | |
| Category Variants Paths |
PIK3CA mutant PIK3CA act mut PIK3CA H1047L PIK3CA mutant PIK3CA exon21 PIK3CA H1047X PIK3CA H1047L |
| Transcript | NM_006218.4 |
| gDNA | chr3:g.179234297A>T |
| cDNA | c.3140A>T |
| Protein | p.H1047L |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| XM_006713658.4 | chr3:g.179234297A>T | c.3140A>T | p.H1047L | RefSeq | GRCh38/hg38 |
| NM_006218.4 | chr3:g.179234297A>T | c.3140A>T | p.H1047L | RefSeq | GRCh38/hg38 |
| XM_011512894.2 | chr3:g.179234297A>T | c.3140A>T | p.H1047L | RefSeq | GRCh38/hg38 |
| XM_011512894 | chr3:g.179234297A>T | c.3140A>T | p.H1047L | RefSeq | GRCh38/hg38 |
| NM_006218.3 | chr3:g.179234297A>T | c.3140A>T | p.H1047L | RefSeq | GRCh38/hg38 |
| XM_006713658 | chr3:g.179234297A>T | c.3140A>T | p.H1047L | RefSeq | GRCh38/hg38 |
| XM_006713658.5 | chr3:g.179234297A>T | c.3140A>T | p.H1047L | RefSeq | GRCh38/hg38 |
| NM_006218 | chr3:g.179234297A>T | c.3140A>T | p.H1047L | RefSeq | GRCh38/hg38 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05455619 | Phase Ib/II | Capivasertib + Fulvestrant + SDX-7320 Alpelisib + Fulvestrant + SDX-7320 | Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/ Her2- Breast Cancer (Amelia-1) | Recruiting | USA | 0 |